CAPESYM INC — Department of Defense SBIR Phase I: DTRA222-002
CAPESYM INC — SBIR Phase I award from Department of Defense.
Phase I SBIR feasibility signal
- Phase I awards fund proof-of-concept work. For capture teams, they mark early interest from Department of Defense in a technical approach.
- Watch for Phase II follow-ons from the same firm/topic family — that conversion path is where budgets and transition pressure rise.
- Obligated amount $167,237. Cross-check similar awards in the same agency and technology tags for going-rate context.
- Topic code DTRA222-002 links this award to a solicitation family — search the same topic stem for incumbents and recompete timing.
- Amount
- $167,237
- Agency
- Department of Defense · Defense Threat Reduction Agency
- Program / Phase
- SBIR · Phase I
- Topic
- DTRA222-002
- Solicitation
- 22.2
- NAICS
- —
- Place of performance
- MA
- Period
- 2023-01-05 → 2023-08-04
Description
Gamma dosimetry is an integral part of radiation safety and protection for a wide range of military operations. For these applications, Geiger Müller (GM) tube is used as the standard gamma dose rate sensor. The cost-to-performance metric for this sensor type has reached a plateau and new sensor materials are needed for the next generation of dosimeters. Recently there has been a vast development in solid state gamma detectors such as silicon photodiodes for dosimetry applications. However, these sensors have temperature sensitivity, non-linearity over a wide dose range and are not nuclear survivable for DoD environments. In this program, we will develop low-cost, high-accuracy rugged nuclear-survivable non-GM gamma dosimeters for DTRA applications. These dosimeters will be applicable to a wide range of doses from background to 100 Gy/hr, and will be operable at temperatures between -50 to 55°C. In phase I, we will demonstrate the operability of the sensors and optimize them to meet the specific performance targets. A dosimeter prototype using this optimal sensor material will be fabricated in Phase II and will be provided to DTRA for evaluation.